Prednisporin is a key asset in the proposed acquisition of Fovea by Sanofi-Aventis

CombinatoRx, Incorporated (NASDAQ: CRXX), today announced that its ophthalmic collaborator, Fovea Pharmaceuticals SA, has entered into a proposed acquisition with Sanofi-Aventis. A CombinatoRx-derived combination drug candidate, Prednisporin, (FOV1101), which is a fixed dose combination of prednisolone and cyclosporine, is the most advanced product asset in the Fovea pipeline, with Phase 2b clinical studies planned for the treatment of persistent allergic conjunctivitis.

“We are pleased to see that a CombinatoRx-derived combination drug candidate has been recognized as a key asset in the proposed acquisition of Fovea, our ophthalmic collaborator,” commented Robert Forrester, Interim President and CEO of CombinatoRx. “This accomplishment reinforces our business strategy of leveraging the CombinatoRx discovery technology platform through strategic collaborations.”